---
title: "Porton Pharma Solutions Ltd. (300363.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300363.SZ.md"
symbol: "300363.SZ"
name: "Porton Pharma Solutions Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:34:52.348Z"
locales:
  - [en](https://longbridge.com/en/quote/300363.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300363.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300363.SZ.md)
---

# Porton Pharma Solutions Ltd. (300363.SZ)

## Company Overview

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.portonpharma.com](https://www.portonpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:10.000Z

**Overall: B (0.39)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.78% |  |
| Net Profit YoY | 165.17% |  |
| P/B Ratio | 1.51 |  |
| Dividend Ratio | 0.60% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 8067839283.78 |  |
| Revenue | 3501362940.82 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.43% | C |
| Profit Margin | 3.67% | C |
| Gross Margin | 30.60% | C |
| Revenue YoY | 11.78% | B |
| Net Profit YoY | 165.17% | A |
| Total Assets YoY | -2.03% | D |
| Net Assets YoY | 1.45% | C |
| Cash Flow Margin | 524.39% | A |
| OCF YoY | 11.78% | B |
| Turnover | 0.41 | C |
| Gearing Ratio | 35.31% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Porton Pharma Solutions Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.78%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "165.17%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.60%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "8067839283.78",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3501362940.82",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.43%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "3.67%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "30.60%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "11.78%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "165.17%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.03%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.45%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "524.39%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "11.78%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "35.31%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 62.00 | 116/215 | 122.91 | 90.55 | 88.52 |
| PB | 1.49 | 40/215 | 2.58 | 2.43 | 2.09 |
| PS (TTM) | 2.27 | 46/215 | 4.11 | 3.72 | 3.26 |
| Dividend Yield | 0.61% | 121/215 | 3.17% | 3.09% | 0.58% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-06T16:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 33% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 15.63 |
| Highest Target | 30.00 |
| Lowest Target | 30.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300363.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300363.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300363.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300363.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**